Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer Signs Pact For Drug Conjugates

by Michael McCoy
June 17, 2013 | A version of this story appeared in Volume 91, Issue 24

Pfizer and CytomX Therapeutics are joining to develop antibody-drug conjugates (ADCs) using Probodies, antibodies from CytomX that remain inert in healthy tissue but are activated in the disease environment. CytomX is eligible for $25 million in up-front, research reimbursement, and preclinical milestone payments and up to $610 million in other milestone payments. Pfizer says the pact will help it advance the next generation of ADCs. Last month the firm revealed that an ADC failed in a Phase III clinical trial as a non-Hodgkin lymphoma treatment.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.